WinstonWınston
STERIS logo

STERIS

STE
62
Medical - Devices · Healthcare
Winston Score
62
Winston is curious
A decent business — some strong pillars, some weaker.

STERIS plc makes products and services that keep medical equipment clean and safe to use. Its core business is sterilization — killing germs on surgical tools, medical devices, and hospital supplies so patients don't get infections. The company sells sterilization equipment, cleaning chemicals, and outsourced sterilization services mainly to hospitals, surgery centers, and medical device manufacturers.

STERIS makes money through a mix of equipment sales, consumable supplies that customers reorder regularly, and long-term service contracts. It operates globally but generates most of its revenue in the United States, and it reported roughly $5 billion in annual revenue in recent years. Its competitive moat comes from sticky customer relationships, regulatory complexity that makes switching difficult, and a large installed base of equipment that drives recurring consumable and service revenue. The key growth driver is the steady rise in surgical procedure volumes worldwide, while the main risk is potential pricing pressure from large hospital systems and group purchasing organizations.

Winston Score History

Politician Trades

18 trades / 12mo

13 Congressional buys and 5 sells on STE in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+7.3% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+51.4% YoY

YoY Growth Rate

Strong earnings growth

Insider Activity

0.3%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$440M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

STERIS is growing revenue at 7% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
43.9%
Healthy — 43.9% gross margin
Operating Margin
19.9%
Healthy — 19.9% operating margin
ROCE
3.5%
Weak — 3.5% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+15.7%
Fast-growing sales (15.7% YoY)
EPS YoY
+50.6%
Earnings growing fast (50.6% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency
8/8 quarters
Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
157%
Turns 157% of profit into real cash
FCF Margin
13.9%
Converts sales into free cash efficiently (13.9%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.27
Conservative — low debt load (0.27)
Interest Cover
17.31x
Comfortably covers interest (17.3x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
26.6x
no trend
Growth-priced — P/E 26.6

P/E above the market average. People are paying up for expected growth.

P/E vs Forward
+8.4
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (26.6 → 18.2)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
1.24%
no trend
Small dividend — 1.24% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend Growth
+10.5%
no trend
Dividend growing fast (10.5% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial